Trial Profile
Phase III Clinical Trial for Assessment of Efficacy and Safety of DA-3002 (Recombinant Human Growth Hormone) in Patients With Turner's Syndrome
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Somatropin (Primary)
- Indications Short stature
- Focus Registrational; Therapeutic Use
- Sponsors Dong-A ST
- 18 Mar 2019 Results presented at the 101st Annual Meeting of the Endocrine Society
- 24 Jul 2018 Status changed from active, no longer recruiting to completed.
- 19 Sep 2017 Status changed from recruiting to active, no longer recruiting.